BioCryst Pharmaceuticals | BCRX - Operating Profit


BioCryst Pharmaceuticals reported $98.46M in Operating Profit for its fiscal quarter ending in June of 2026.





Operating Profit Change Date
Alnylam Pharmaceuticals USD 112.6M 24.99M Jun/2026
BioCryst Pharmaceuticals USD 98.46M 161.92M Jun/2026
Chugai Pharma JPY 160.86B 2.09B Jun/2026
Daiichi Sankyo JPY 85.1B 4.44B Jun/2026
DBV Technologies USD -47.9M 2.85M Mar/2026
Enanta Pharmaceuticals USD -23.54M 98.15M Dec/2024
Gilead Sciences USD 3.85B 1.17B Jun/2026
GlaxoSmithKline GBP 2.6B 312M Jun/2026
Glaxosmithkline GBP 2.29B 3.08M Mar/2026
Incyte USD 700.4M 376.22M Jun/2026
Ionis Pharmaceuticals USD -102.29M 15.71M Jun/2026
Karyopharm Therapeutics USD -26.76M 8.92M Mar/2026
Neurocrine Biosciences USD 219.9M 5.3M Jun/2026
Novavax USD 20.94M 100.32M Dec/2025
PTC Therapeutics USD 45.89M 127.51M Mar/2026
Regeneron Pharmaceuticals USD 1.42B 675.7M Jun/2026
Roche Holding CHF 11.46B 1.91B Jun/2026
Sarepta Therapeutics USD 13.29M 345.14M Jun/2026
Ultragenyx Pharmaceutical USD -75M 141M Jun/2026
Vertex Pharmaceuticals USD 1.27B 129.9M Jun/2026